Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US81663L2007
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00XDHY5P9
WGS
GeneDx Holdings Corp
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $GRLZ
NAME
GeneDx Holdings Corp
ISIN
US81663L2007
TICKER
WGS
MIC
XNAS
REUTERS
WGS.OQ
BLOOMBERG
WGS US
Thu, 15.01.2026       GeneDx
US81663L2007

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders. If you currently own GeneDx stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the com...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.01.2026       GeneDx
US81663L2007

GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for the fourth quarter and full year of 2025. “In 2025, GeneDx continued its journey of transforming the standard of pediatric care by accelerating the use of genomics to the earliest moment...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.01.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo Health, the leader in AI-powered healthcare intelligence. Through the partnership, GeneDx’s Infinity™ will leverage real-world patient insights from Komodo’s Healthcare Map®, to create the most compreh...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.01.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced GenomeDx Prenatal™, whole genome sequencing (WGS) designed to deliver clear, reliable answers during one of the most critical moments in pregnancy care. The phenotype-informed, trio-based test is intended for pregnancies with fetal anoma...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 06.01.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights today announced Linda Genen, MD, MPH as Chief Medical Officer to further strengthen the company’s commitment to delivering earlier answers and better outcomes for families through genomic insights. This press release features multimedia. View the full r...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 05.01.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a record-setting year for its Medical Affairs and research programs, reinforcing its position as the global leader in rare disease genomics. In 2025, GeneDx published 79 peer-reviewed studies bringing its total to over 1,100 peer-reviewe...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 30.12.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15 in San Francisco, CA. Katherine Stueland, President and Chief Executive Officer, will participate in a presentation on Wedne...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 15.12.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that the GUARDIAN (Genomic Uniform-screening Against Rare Disease In All Newborns) study has been recognized as part of JAMA’s annual Research of the Year Roundup. This highly selective honor is reserved for the most impactful scientific...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Sun, 30.11.2025       GeneDx
US81663L2007

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Nov. 30, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders....
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.11.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will unveil research findings during four key sessions at the 2025 National Society of Genetic Counselors (NSGC) Annual Meeting. “GeneDx is at the forefront of genomic discovery, accelerating gene-disease insights, advancing long-rea...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 04.11.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences: Stifel 2025 Healthcare Conference New York, New York Fireside Chat: Wednesday, November 12 at 2:00 p.m. ET Jefferies Global Healthcare Conference Lo...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.10.2025       GeneDx
US81663L2007

GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the third quarter of 2025. “GeneDx’s accelerated growth reflects more than business momentum - it’s proof of the profound impact we’re making for families navigating rare disease and the broader...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.10.2025       GeneDx
US81663L2007

SAN FRANCISCO, Oct. 27, 2025 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP reminds GeneDx Holdings Corp. (NASDAQ: WGS) investors that the firm is investigating potential legal claims relating to whether the company misled investors about its health intelligence platform called Centrellis. Current shareholder...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.10.2025       GeneDx
US81663L2007

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders. If you currently own GeneDx stock and acquired shares on or before January 18, 2022, you may be able to seek corporate governance reforms, the return of fun...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.10.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced data and presentations at the International Consortium on Newborn Sequencing (ICoNS), underscoring the company’s leadership in driving genomic newborn screening (gNBS) from research into real-world clinical implementation. As the labor...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.10.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its whole genome and exome tests associated with causes of life-threatening diseases or genetic disorders to aid in diagnosis of symptomatic...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.10.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Dr. Mimi Lee, MD, PhD, as Chief Precision Medicine Officer. Dr. Lee will spearhead GeneDx’s vision to unlock the power of genomics to help every person live their healthiest life. As Chief Precision Medicine Officer, Dr. Lee will lead...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.10.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Florida State University has selected GeneDx as one of its partners for the recently passed Sunshine Genetics Act, a groundbreaking initiative establishing the nation’s first state-backed genomic newborn screening (gNBS) program. The S...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.10.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the Autism Partnership Program to expand access to its industry leading exome and genome testing – the only autism testing program committed to delivering answers to families in weeks. Jaguar Gene Therapy joins the program as the foundin...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.10.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced pioneering scientific contributions that will be presented at the American Society of Human Genetics (ASHG) Annual Meeting. At ASHG, GeneDx will unveil research findings drawn from GeneDx Infinity™, a dataset of nearly one million exom...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 07.10.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the third quarter of 2025 before the market opens on Tuesday, October 28, 2025. Management will host a conference call that day to discuss third quarter 2025 financial and operating results at 8:30 a...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.10.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, alongside Mass General Brigham, Ariadne Labs, Boston Children’s Hospital, Albert Einstein College of Medicine, the Association of Public Health Laboratories (APHL), Case Western Reserve University, Baylor College of Medicine, and Illumina, today announc...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 30.09.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Lisa Gurry as Chief Business Officer (CBO), effective immediately. In this newly-created role, Gurry will lead GeneDx’s next phase of transformation, advancing data and information services across biopharma, health sys...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 25.09.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will introduce pediatricians to GeneDx’s Infinity, the company’s proprietary dataset, at the American Academy of Pediatrics (AAP) National Conference & Exhibition taking place this weekend September 26 to 30 in Denver, CO. Infinit...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.09.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Thomas Fuchs, Dr.sc., Chief AI Officer at Eli Lilly and Company, to its board of directors. “With the world’s largest rare disease data set, we’re only beginning to realize AI’s full potential to deliver faster, more...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Sun, 31.08.2025       GeneDx
US81663L2007

NEW YORK, Aug. 31, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from al...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 26.08.2025       GeneDx
US81663L2007

NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from al...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 19.08.2025       GeneDx
US81663L2007

NEW YORK, Aug. 18, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from al...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.08.2025       GeneDx
US81663L2007

NEW YORK, Aug. 13, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from al...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Fri, 08.08.2025       GeneDx
US81663L2007

NEW YORK, Aug. 8, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from all...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Sun, 03.08.2025       GeneDx
US81663L2007

NEW YORK, Aug. 3, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from al...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 29.07.2025       GeneDx
US81663L2007

GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the second quarter of 2025. “Crossing the $100 million revenue mark and delivering our fourth consecutive profitable quarter is a major milestone for GeneDx, putting us on a path for more growth...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 29.07.2025       GeneDx
US81663L2007

NEW YORK, July 28, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from al...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 28.07.2025       GeneDx
US81663L2007

LOS ANGELES, July 28, 2025 /PRNewswire/ -- News provided by DJS Law Group LLP The DJS Law Group reminds investors that it is investigating claims GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of securities laws.  The investigation centers on whether the Company made false and/or misleading statements or failed to...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 28.07.2025       GeneDx
US81663L2007

LOS ANGELES, July 28, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of the securities laws....
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 22.07.2025       GeneDx
US81663L2007

LOS ANGELES, July 22, 2025 /PRNewswire/ -- The DJS Law Group reminds investors that it is investigating claims GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of securities laws.  The investigation centers on whether the Company made false and/or misleading statements or failed to disclose material information rele...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 21.07.2025       GeneDx
US81663L2007

NEW YORK, July 21, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from al...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 21.07.2025       GeneDx
US81663L2007

SAN FRANCISCO, July 21, 2025 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises GeneDx Holdings Corp. (NASDAQ: WGS) investors that the firm is investigating potential legal claims relating to alleged false statements about its health intelligence platform called Centrellis. Current shareholders are encouraged to contact the firm. INVESTO...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.07.2025       GeneDx
US81663L2007

NEW YORK, July 15, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public....
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Fri, 11.07.2025       GeneDx
US81663L2007

NEW YORK, July 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from al...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 10.07.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the second quarter of 2025 before the market opens on Tuesday, July 29, 2025. Management will host a conference call that day to discuss second quarter 2025 financial and operating results at 8:30 a....
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.06.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced new data from the SeqFirst study team conducted in partnership with the clinical genetics team at Seattle Children’s supporting the application of rapid exome sequencing (rES) and rapid genome sequencing (rGS) as a first-tier test for no...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.06.2025       GeneDx
US81663L2007

NEW YORK, June 23, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting f...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.06.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announces the American Academy of Pediatrics (AAP) issued updated guidance to now recommend exome and genome sequencing as first-tier tests for children with global developmental delay (GDD) or intellectual disability (ID) in most circumstances because...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.06.2025       GeneDx
US81663L2007

Galatea Bio and Fabric Genomics, a GeneDx company, announced today a strategic collaboration to enhance genetic testing by incorporating both rare pathogenic variant analysis and polygenic risk scoring (PRS) to assess genetic susceptibility to common diseases. The initial offering will include an inherited cardiovascular gene panel based on Amer...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.06.2025       GeneDx
US81663L2007

NEW YORK, June 18, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting fr...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.06.2025       GeneDx
US81663L2007

LOS ANGELES, June 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of the securities laws....
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Fri, 13.06.2025       GeneDx
US81663L2007

NEWTOWN, Pa., June 13, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving GeneDx Holdings Corp. ("GeneDx") (NASDAQ: WGS), resulting from allegations of providing potentially misleading business information to the investing public....
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.06.2025       GeneDx
US81663L2007

LOS ANGELES, June 12, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of the securities laws....
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.06.2025       GeneDx
US81663L2007

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public. So What: If you purchased GeneDx securities y...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink